Vander Ark, CR , Reynolds, EW: Clinical evaluation of glucagon by continuous infusion in the treatment of low cardiac output states. American Heart Journal, 79: 481-4, 1970.
4.
Linhart, JW, Barold, SS, Cohen, WS, Hildner, FJ, and Samet, P.: Cardiovascular effects of glucagon in man. American Journal of Cardiology, 22: 706-10, November, 1968.
5.
Whitsitt, LS, Lucchesi, BR: Effects of beta-receptor blockade and glucagon on the atrioventricular transmission system in the dog. Circ. Res., 23: 585-89, 1968.
6.
Williams, JF: Glucagon and the cardiovascular system (Editorial). Annals of Internal Medicine, Vol. 71. No. 2, 419-22, August, 1969.
7.
Rowe, GG: Systemic and coronary hemodynamic effects of glucagon. American Journal of Cardiology, 25: 670-82, June, 1970 .
8.
Cohn, KE, Agmon, J., Gamble, OW: The effect of glucagon on arrhythmias due to digitalis toxicity. American Journal of Cardiology, 25: 683-89, June, 1970 .
9.
Bacaner, MB: Treatment of ventricular fibrillation and other acute arrhythmias with bretylium tosylate. American Journal of Cardiology, 21: 530-43, April, 1968.
10.
Taylor, SH, Saxton, C., Davies, PS, Stoker, JB: Bretylium tosylate in prevention of cardiac arrhythmias after myocardial infarction . British Heart Journal, 32: 326-9, 1970.
11.
Castaneda, AR, Bacaner, MB: Effect of bretylium tosylate on the prevention and treatment of postoperative arrhythmias. American Journal of Cardiology, 25: 461-66, April, 1970.
12.
Day, HW, Bacaner, M.: Use of bretylium tosylate in the management of acute myocardial infarction . American Journal of Cardiology. 27: 177-90. February. 1971.
13.
Gould. L.Zahir. M. et al: Treatment of cardiac arrhythmias with phentolamine. American Heart Journal.78: 189-931969.
